GEVA

Synageva BioPharma Corp. Press Releases

$97.1295
*  
3.4705
3.45%
Get GEVA Alerts
*Delayed - data as of Mar. 3, 2015 10:18 ET  -  Find a broker to begin trading GEVA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GEVA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015
2/27/2015 8:40:00 AM - PR Newswire


Synageva BioPharma Reports 2014 Full Year Financial Results
2/26/2015 4:05:00 PM - PR Newswire


Synageva BioPharma To Present At The Cowen and Company Health Care Conference
2/25/2015 11:35:00 AM - PR Newswire


FDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date
2/23/2015 8:00:00 AM - PR Newswire


Synageva BioPharma To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26
2/19/2015 9:00:00 AM - PR Newswire


Synageva European Patent Issued For Treatment Of LAL Deficiency
2/18/2015 7:30:00 AM - PR Newswire


Synageva BioPharma Announces Presentations At 11th Annual World Symposium
2/11/2015 7:30:00 AM - PR Newswire


CPA:17 - Global Acquires $22 Million Office and Data Center Leased to iHeartCommunications, Inc.
2/11/2015 7:30:00 AM - PR Newswire


Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
1/26/2015 7:30:00 AM - PR Newswire
▼-18.32 % Price Change since this news event. The Volume Ratio is 0.41.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Announces Pricing of Public Offering of Common Stock
1/6/2015 7:07:00 PM - PR Newswire
▲3.12 % Price Change since this news event. The Volume Ratio is 8.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Announces A 2.5 Million Share Proposed Public Offering Of Its Common Stock
1/5/2015 4:15:00 PM - PR Newswire
▼-2.01 % Price Change since this news event. The Volume Ratio is 3.72.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Announces New Pipeline Programs And Other Company Progress
1/5/2015 7:30:00 AM - PR Newswire
▲3.18 % Price Change since this news event. The Volume Ratio is 2.5.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alliance Data Announces New Stock Repurchase Program
1/5/2015 7:30:00 AM - PR Newswire


Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
12/23/2014 11:26:00 AM - PR Newswire


Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
12/23/2014 11:26:00 AM - PR Newswire
▲5.79 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST
12/17/2014 8:00:00 AM - PR Newswire
▲11.16 % Price Change since this news event. The Volume Ratio is 1.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB
12/15/2014 7:00:00 AM - PR Newswire
▲6.38 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day